Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MNC-168 in advanced malignant solid tumors
NCT05383703Phase 1Completed
- Sponsor
- MoonBio
- Start
- Oct 2022
- Primary completion
- Jul 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MNC-168 in malignant solid tumor, sponsored by MoonBio. Primary endpoint: Safety and tolerability indexes at 2 years. Started Oct 2022; status: completed.
02
Drugs
MNC-168
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT05383703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05383703.